When was Illumina founded?

Illumina was founded in 1993 and raised its 1st funding round 7 years after it was founded.

Where is Illumina located?

Illumina is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Illumina have?

As of Apr 30, 2026, the latest employee count at Illumina is 9625.

Is Illumina a funded company?

Illumina is a funded company, having raised a total of $28M across 11 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jan 10, 2000.

When was the latest funding round of Illumina?

Illumina's latest funding was a $***** Grant (prize money) round on Jan 01, 2020, with participation from 1 investor.

What is the annual revenue of Illumina?

Annual revenue of Illumina is more than $1B as on Dec 31, 2025

Where does Illumina rank among its competitors?

Illumina ranks 2nd amongst 522 active competitors, of which 63 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Arbor Biotechnologies, which secured an undisclosed amount in Oct, 2025.

Who are the top competitors of Illumina?

Illumina's top competitors include PacBio, Quanterix and BioLife Solutions. Among them, Arbor Biotechnologies secured the most recent funding round in October, 2025.

Illumina - 2026 Company Profile, Team, Funding, Competitors & Financials

Illumina is a public company based in San Diego (United States), founded in 1993 by David R Walt, John Stuelpnagel, Anthony Czarnik, Mark Chee and Larry Bock. It operates as a Developer of technologies for analysis of genetic variation and function. Illumina has raised $28M in funding from investors like Dow Chemical Company, Lombard Odier and P E Corporate Services. The company has 522 active competitors, including 63 funded and 78 that have exited. Its top competitors include companies like PacBio, Quanterix and BioLife Solutions.

Company Details

Developer of technologies for analysis of genetic variation and function. The company provides laboratory instruments, kits, and reagents for research, drug development, and the development of molecular tests. The product categories include gene panel and array finder, microarray kits, clinical research, and IVD products.

Website: www.illumina.com
Social
Email ID: *****@illumina.com
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

1993

Location

San Diego, United States

Stage

Public

Total Funding

$28M in 11 rounds

Latest Funding Round

Grant (prize money), Jan 01, 2020, $*****

Investors

Dow Chemical Company & 33 more

Ranked

2^nd among 522 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

9,625 as on Apr 30, 2026

Investment & Acquisitions

Juno Bio & 85 more

Similar Companies

PacBio & 621 more

Exit Details

Public

View Illumina's full profile

Illumina is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Illumina, Inc. CIN: 62840591 , United States, Active	Sep 04, 2009	$1B+ (As on Dec 31, 2024)	-	-
ILLUMINA INDIA BIOTECHNOLOGY PRIVATE LIMITED CIN: U51100HR2018FTC074675 , India, Active	Jun 20, 2018	₹100 - ₹500 Cr (As on Mar 31, 2025)	-
Illumina, Inc. CIN: 330804655 , United States, Active	Dec 31, 1999	$1B+ (As on Dec 31, 2025)	5088 (As on Dec 31, 2024)	-
ILLUMINA DENMARK ApS CIN: 34087423 , Denmark, Active	Dec 06, 2011	-	16 (As on Mar 31, 2024)
ILLUMINA INC CIN: 1110803 , United States, Active	May 15, 2000	$1B+ (As on Dec 31, 2018)	-	-

Illumina got listed on Jul 28, 2000.

Click here to take a look at Illumina's IPO in detail

Illumina has raised a total funding of $28M over 11 rounds. Its first funding round was on Jan 10, 2000. Its latest funding round was a Grant (prize money) round on Jan 01, 2020 for $*****. 1 investor participated in its latest round. Illumina has 34 institutional investors.

Here is the list of recent funding rounds of Illumina:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 01, 2020	9096058	Grant (prize money)	9798221	4962374	9571937	2054710
Aug 01, 2019	9033850	Grant (prize money)	8928111	2082460	8008866	Europa
Aug 01, 2014	7915597	Grant (prize money)	2430015	7948443	2846599	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Illumina's funding rounds and investors

The founders of Illumina are David R Walt, John Stuelpnagel, Anthony Czarnik, Mark Chee and Larry Bock. Jacob T is the CEO of Illumina.

Here are the details of Illumina's key team members:

David R Walt: Former Co-Founder of Illumina and founder of 2 other companies, VIZGEN and Illumina Ventures. They are also an angel investor in 2 startups and serve on the board of 1 company.
Contact Info: 1 email address
John Stuelpnagel: Former Co-Founder of Illumina. They are also an angel investor in 1 startup and serve on the board of 1 company.
Anthony Czarnik: Former Co-Founder of Illumina.
Mark Chee: Co-Founder of Illumina.
Contact Info: 1 email address
Larry Bock: Co-Founder of Illumina.
Contact Info: 1 email address

View details of Illumina's Founder profiles and Board Members

Illumina's employee count trend

Illumina has 9,625 employees as of Apr 26. Here is Illumina's employee count trend over the years:

Uncover Illumina's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Illumina include PacBio, Quanterix and BioLife Solutions. Here is the list of Top 10 competitors of Illumina, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PacBio 2004, Menlo Park (United States), Public	Developer of instrument systems and software for real-time sequencing of single-molecules	$410M	Deerfield, Kleiner Perkins & 24 others	72/100
2nd	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Saints Capital, Gershon Capital & 32 others	71/100
3rd	Quanterix 2007, Cambridge (United States), Public	Developer of assay kits for ultra-sensitive biomarker detection	$99.5M	T. Rowe Price, Cormorant Asset Management ... & 15 others	71/100
4th	BioLife Solutions 1987, Bothell (United States), Public	Developer of cell and gene therapies with the integrity of a single cell	-	-	67/100
5th	Complete Genomics 2006, San Jose (United States), Acquired	Developer of DNA sequencing platform for human genome sequencing and analysis	$125M	Enterprise Partners Venture Capital, Orbimed ... & 8 others	66/100
6th	Biocare Medical 1997, Concord (United States), Acquired	Manufacturer of primary antibodies and instruments for immunohistochemistry applications	$85M	Excellere Partners, GHO Capital Partners & 3 others	65/100
7th	Arbor Biotechnologies 2016, Cambridge (United States), Series C	Provider of genomic technologies and drug discovery platform	$304M	TCG Crossover, Temasek & 27 others	65/100
8th	Zageno 2015, Cambridge (United States), Series C	Marketplace and life science research community for biotech research kits	$121M	General Catalyst, Grazia Equity & 5 others	64/100
9th	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	CPE, Guotai Junan Securities & 13 others	64/100
10th	PerkinElmer 1931, Waltham (United States), Funding Raised	Provider and manufacturer of medical instruments and supplies for the healthcare industry	-	Tekla Capital Management, New Mountain Capital ... & 2 others	63/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Illumina's competitors? Click here to see the top ones

Illumina has made 69 investments in companies including Juno Bio and Pillar Biosciences. Illumina has also acquired 17 companies including Somalogic and Fluent BioSciences.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jul 16, 2026	Investments	Juno Bio	2018	London (United Kingdom)
Jun 23, 2025	Acquisition	Somalogic	1999	Boulder (United States)
May 27, 2025	Investments	Pillar Biosciences	2014	Natick (United States)